Septerna Says SEP-631 Well-Tolerated With Adverse Event Profile Comparable To Placebo
ReutersMar 1, 2026 2:47 PM
March 1 (Reuters) - Septerna Inc SEPN.O:
SEPTERNA ANNOUNCES POSITIVE PHASE 1 DATA FOR SEP-631, AN ORAL MRGPRX2 NAM FOR THE TREATMENT OF MAST CELL-DRIVEN DISEASES, AND OUTLINES INITIAL PHASE 2 DEVELOPMENT STRATEGY
SEPTERNA INC - SEP-631 WELL-TOLERATED WITH ADVERSE EVENT PROFILE COMPARABLE TO PLACEBO
SEPTERNA INC - PHASE 2 DEVELOPMENT FOR CHRONIC SPONTANEOUS URTICARIA PLANNED FOR 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Airbnb Stock Outlook 2026: What Investors Should Watch
TradingKey - Airbnb (ABNB), a large company in the gig economy, has developed a massive technology company that is able to grow considerably by using the internet and will continue to operate profitably going forward.TradingKey
17 hours ago
Korean Stocks Up 47% YTD: How to Join the Rally
TradingKey - Since the start of 2026, South Korea’s KOSPI Index has been on a tear — rising more than 47% so far this year and lifting the market’s capitalization to ninth place globally. That performance makes it one of the brightest stars among major equity benchmarks.TradingKey
Sat, Feb 28
Gold and Silver February Summary: Safe-Haven and Speculation Resonance, Precious Metals See Double Boost From Sentiment and Speculative Funds
TradingKey - In February 2026, the precious metals market strengthened significantly against a backdrop of rising geopolitical risks and fluctuating macroeconomic expectations. Gold (XAUUSD) and silver (XAGUSD) not only extended their strong performance since the beginning of the year but also showed signs of accelerated upward momentum toward the end of the month.TradingKey
Sat, Feb 28
How Tesla Survives the Cold Winter, Will Tesla Stock Continue to Fall in 2026?
TradingKey — Recently, weighed down by earnings missing expectations and factors such as AI bubble and disruption theories, Tesla (TSLA) shares have continued to slide, falling nearly 20% from their December 2025 peak.TradingKey
Sat, Feb 28
